RTX will have a new version that allows subcutaneous injection (vs current intravenous). I'm wondering if this will dramatically decrease the cost of RTX, due to reducing/ removing the "infusion cost" - which is $2k at OMI from what I've read on this forum..
- "(Halozyme) also announced last week that the FDA has accepted Genentech's biologics license application for subcutaneous formulation of rituximab using our ENHANZE technology in multiple blood cancer indications. This development represents a meaningful step towards bringing rituximab SC to patients in the United States. "
- http://seekingalpha.com/article/402...rley-q3-2016-results-earnings-call-transcript